MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of MaxCyte (NASDAQ:MXCT) from a hold rating to a sell rating in a research report released on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

MaxCyte Trading Down 2.7%

Shares of MXCT opened at $1.43 on Friday. The stock has a market cap of $152.54 million, a PE ratio of -3.25 and a beta of 1.22. MaxCyte has a 1 year low of $1.26 and a 1 year high of $5.20. The stock has a 50 day simple moving average of $1.57 and a 200-day simple moving average of $1.68.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The company had revenue of $6.41 million during the quarter, compared to the consensus estimate of $8.37 million. On average, sell-side analysts forecast that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

A number of hedge funds have recently added to or reduced their stakes in the stock. CWM LLC increased its position in MaxCyte by 92.7% in the 2nd quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after acquiring an additional 5,836 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of MaxCyte by 39.5% in the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after purchasing an additional 10,263 shares in the last quarter. Kwmg LLC raised its position in MaxCyte by 75.8% in the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after purchasing an additional 11,135 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in MaxCyte by 7,935.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock worth $26,000 after buying an additional 11,665 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in MaxCyte in the 2nd quarter valued at $26,000. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.